Oncology Development Program Lead News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Bristol Myers Squibb Announces Update on Phase 3 CheckMate -548 Trial Evaluating Patients with Newly Diagnosed MGMT-Methylated Glioblastoma Multiforme Bristol Myers Squibb today announced an update on CheckMate -548, a Phase 3 trial evaluating the addition of Opdivo to the current standard of care versus placebo plus the standard of care in patients with newly diagnosed glioblastoma multiforme with O6-methylguanine-DNA methyltransferase promoter methylation following surgical resection of the tumor. Following a routine review of the study by an independent data … Bristol Myers Squibb (NYS...

Bristol-Myers: Phase 3 CheckMate -548 Trial Will Not Meet Primary Endpoint Of Overall Survival NEW YORK CITY (dpa-AFX) - Biopharmaceutical company Bristol Myers Squibb Co. (BMY) said Wednesday that following a routine review of the CheckMate -548 Phase 3 trial by an independent data monitoring committee or DMC, the company was informed that based on the number of events to date, the study will not meet its primary endpoint of overall survival in patients with no baseline corticosteroid use or in the overall randomized population. The DMC also indicated there were no safety concerns observed ...